Distinct commensals induce interleukin-1 via NLRP3 inflammasome in inflammatory monocytes to promote intestinal inflammation in response to injury
With appropriate monitoring and support, most patients successfully navigate the initial treatment period and go on to achieve meaningful improvements in metabolic health
Key players today include Mounjaro (tirzepatide) a dual-agonist of GLP-1 and GIP receptors and coming soon, Retatrutide a triple-receptor agonist (GLP-1, GIP and glucagon) that has shown even stronger early results
Lm m vt thm, nm, tn nhang, cho da u mu hn
Negative Side Effects While Semaglutide does increase lipolysis, it can also cause loss of muscle mass, which is concerning, especially for older people who naturally lose muscle as they age
Because these medications are customized, theyre not FDA-approved in the same way as commercial drugs, but they do use FDA-approved ingredients